Pancreatitis, Acute, SIRS
Conditions
Keywords
Severe acute pancreatitis, Haemodynamic monitoring, Cytokine removal, Vasopressor dependency index
Brief summary
Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic. With regard to a marked inflammatory response (cytokine storm) during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach. This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb®-device on haemodynamics (primary endpoint) and several secondary outcomes.
Detailed description
Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic. Severity and mortality are associated to an early systemic inflammatory response syndrome (SIRS) and to septic complications at a later stage of disease. With regard to a marked inflammatory response (cytokine storm) during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach. This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb® device on haemodynamics (primary endpoint) and several secondary outcomes. Patients with high probability of SAP (APACHE-II-score ≥10) are eligible for 7 days after the onset of pain. The patients will be treated for 48h with two consecutive 24h sessions of cytokine absorption with the CytoSorb®-device. All patients will be under haemodynamic Monitoring with transpulmonary thermodilution The primary endpoint is defined as an improvement of the vasopressor dependency index of ≥20% (if no vasoactive drugs are used at baseline, the cardiac power index cardiac power index (CPI) will be used as primary endpoint). The outcome analysis will be based on comparison of the incidence of the primary endpoint in 30 Intervention patients compared to 60 matched controls.
Interventions
DEVICECytoSorb
Two consecutive 24h treatments with the CytoSorb-device
Sponsors
CytoSorbents Europe GmbH
Technical University of Munich
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Inflammatory cytokine removal by Cyto Sorb treatment
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Proven acute pancreatitis: * typical pain * at least 3-fold increase in serum lipase * onset of pain within 7 days before inclusion AND * APACHE-II ≥10 AND * ≥1 criterion of severe sepsis AND * Haemodynamic monitoring with transpulmonary thermodilution AND * ≥ 1 marker of poor prognosis of acute pancreatitis: * Haematocrit \> 44% (men), \>40% (women) * Blood glucose \> 125 mg/dL * C-reactive protein (CRP) \> 10mg/dL * Computed tomography score category C-E * Age \>55 years * Leukocytes \>16 G/L * Glutamate oxaloacetate transferase (GOT) \>250 U/L * Lactate dehydrogenase (LDH) \>350 U/L * Calcium \<2,0mmol/L
Exclusion criteria
* pregnancy * lack of informed consent of patient or representative * pre-existing disease with life expectancy \<3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Haemodynamics | Within 48h after the onset of CytoSorb treatment | Improvement of the vasopressor dependency index \>=20%. (Improvement of cardiac power index \>=20% in case of no vasopressor use at baseline) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality-1 | 28 days from inclusion into the study | 28-days-mortality |
| Mortality-2 | From admission to the ICU until discharge or transfer from the ICU (up to one year) | ICU-mortality |
| Mortality-3 | From admission to discharge from the hospital (up to one year) | Hospital-mortality |
| Inflammation | Within 48h after the onset of CytoSorb treatment | IL-6, CRP and PCT-values levels compared to before CytoSorb treatment |
| Respiratory outcome | Within 28 days after the onset of CytoSorb treatment | Ventilator-free days |
| Renal function and its Change over time | Within 28 days after the onset of CytoSorb treatment | Daily classification according to KDIGO; comparison vs. before Cyto Sorb treatment |
Contacts
Primary ContactWolfgang Huber, Professor
Backup ContactTobias Lahmer, MD
Outcome results
None listed